Humans lost the enzyme cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH), abolishing endogenous synthesis of N-glycolylneuraminic acid (Neu5Gc) and thereby altering the composition of sialic acids on cell-surface glycans. This evolutionary change reshaped immune and metabolic interactions at the cell surface, but its impact on how metabolic stress influences colorectal cancer (CRC) progression has not been fully defined. The authors investigated whether a human-like sialome—modeled by genetic Cmah deficiency—modulates the tumor response to metabolic perturbation, specifically chronic hyperglycemia, in the context of spontaneous intestinal tumorigenesis driven by Apc mutation.
The study used a spontaneous CRC model that combined a conditional Apc mutation with Cmah deficiency to recapitulate the human sialic acid repertoire (referred to in the source as CPC-Apc Cmah -/- mice). The investigators compared these mice with wild-type (WT) counterparts under two metabolic states: euglycemia and chronic hyperglycemia induced by low-dose streptozotocin. The goal was to assess genotype-specific differences in tumor initiation, growth, histopathology, and the tumor immune microenvironment. The abstract reports qualitative and comparative findings; precise experimental numbers, timepoints, and statistical details were not provided in the source text.
Under normal (euglycemic) conditions, CPC-Apc Cmah -/- mice showed a reduced tumor phenotype relative to WT mice: fewer polyps and a lower overall tumor burden were observed. This indicates that loss of CMAH and the resulting human-like sialome can change baseline CRC development in this genetic model. The data suggest that sialome composition influences tumor initiation or early progression in the absence of overt metabolic stress.
Tumors from CPC-Apc Cmah -/- mice under euglycemia displayed marked changes in the immune microenvironment. The authors report increased infiltration of leukocytes into tumors, a relative enrichment of B cells, and reduced expression of PD-1 on both B cells and cytotoxic CD8+ T cells. These findings indicate an altered immune surveillance or activation state associated with a human-like sialome that could contribute to the observed reduction in polyp number and burden in euglycemic Cmah -/- mice.
Induction of chronic hyperglycemia using low-dose streptozotocin produced a striking, genotype-specific effect. Although hyperglycemia levels were comparable between genotypes, tumor progression was dramatically exacerbated only in CPC-Apc Cmah -/- mice. In these mice, hyperglycemia was associated with increased tumor burden, accelerated lesion development, and progression toward high-grade dysplasia. By contrast, WT mice did not show an equivalent exacerbation of tumor progression under the same hyperglycemic conditions. These results support a model in which a human-like sialome increases susceptibility to metabolic stress-driven CRC progression.
Histopathological analyses revealed that tumors from hyperglycemic CPC-Apc Cmah -/- mice exhibited increased mesenchymal expansion. The authors note a close resemblance between these murine lesions and colorectal tumors taken from diabetic patients, suggesting that the combined genetic and metabolic perturbations in the model capture relevant morphological features of diabetes-associated CRC in humans.
The combination of conditional Apc mutation with Cmah deficiency (CPC-Apc Cmah -/-) is presented as a translationally relevant model to investigate the links between diabetes and colorectal carcinogenesis. The model recapitulates a human-like sialome while allowing experimental induction of chronic hyperglycemia; together these elements revealed interactions between glycan biology, the immune microenvironment, and metabolic stress that affect tumor progression.
The abstract and provided source text summarize principal findings but do not report several key experimental details within this excerpt: cohort sizes, precise hyperglycemia measurement values and duration, timing of tumor assessments, quantitative immune-cell frequencies, and statistical outcomes. Those methodological and quantitative specifics were not reported in the provided text and therefore cannot be restated here.
In summary, the preclinical data indicate that loss of CMAH and a resultant human-like sialome modulate both baseline tumor biology and the response to metabolic stress. Specifically, while Cmah deficiency was associated with reduced tumor burden under euglycemia and distinct immune microenvironment remodeling, it paradoxically rendered tumors vulnerable to dramatic exacerbation when chronic hyperglycemia was induced. The CPC-Apc Cmah -/- mouse is proposed as a useful model for further mechanistic and translational studies on diabetes-associated CRC, including exploration of immune, metabolic, and glycan-targeted interventions. The abstract notes no reported conflicts of interest. Detailed methods and full quantitative results should be consulted in the full preprint for experimental replication and critical appraisal.